NEW YORK, September 11, 2025--(BUSINESS WIRE)--Tema ETFs ("Tema"), the New York-based provider of innovative exchange traded funds (ETFs), today announced the launch of the Tema International Durable ...

DRI to assist in advancing potential of iTOL-100 to enable engraftment and long-term survival of transplanted insulin producing stem cells without the use of chronic immunosuppression Pre-clinical ...

Intech (ITOL) has delivered a 88.89% change over the past year, with a 52-week range between 17.80 and 47.40. What Is the Average Daily Trading Volume of Intech (ITOL)? The average daily trading ...

Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression Kadimastem and iTolerance believe that the ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. NLS Pharmaceutics ( (NLSP)) has shared an ...

Kadimastem Ltd. and Itolerance Inc. have held a type B pre-IND meeting with the FDA regarding the development of ITOL-102, an investigational biologic for the treatment and potential cure of type 1 ...

iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance ...

The ITOL ETF is currently trading at $25.34, which represents a -0.39% change. Over the past 52 weeks, the ETF has traded as high as $25.44 and as low as $25.44. The expense ratio of ITOL is 0.6%.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP”) (“NLS”) and Kadimastem Ltd. (“Kadimastem”), a clinical-stage company specializing in "off-the-shelf" allogeneic cell therapy products for neurodegenerative ...

Tema ETF Trust - Tema International Durable Quality ETF is an exchange traded fund launched and managed by Tema ETFs LLC. The fund is co-managed by Tidal Investments LLC. It invests in public equity ...